1 Min Read
Feb 16 (Reuters) - Tracon Pharmaceuticals Inc :
* Tracon Pharmaceuticals announces first patient dosed in phase 3 tappas trial of TRC105 in angiosarcoma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.